Loading stock data…
ELMD
$25.60-0.11 (-0.43%)
Market ClosedLast close May 1
Electromed, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Electromed, Inc. in the Healthcare sector is trading at $25.60. The stock is currently 17% below its 52-week high of $30.73, remaining 3.3% above its 200-day moving average. Technical signals show neutral RSI of 55 and bullish MACD crossover, explaining why ELMD maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$25.60
Potential Downside
11.1%
Whystock Fair Value$22.76
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The co...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$210.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.70
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.79%
Volume
Today's trading volume
36,198
Recent News
How The Electromed (ELMD) Narrative Is Shifting With New Targets And Assumptions
Electromed’s updated analyst work now points to a fair value of US$37.00, aligned with the prior US$37.00 target, keeping the headline price objective steady. Bullish and bearish analysts are reading this unchanged target through very different lenses, with one side seeing reinforced support for the current valuation and the other highlighting limited room for error. As you read on, you will see how to track these shifts in the story and what they might mean for your own view on Electromed...
Electromed (ELMD) Reports 13th Consecutive Quarter of Revenue and Profit Growth
Electromed Inc. (NYSEAMERICAN:ELMD) is one of the most promising micro-cap stocks according to analysts. On February 10, Electromed achieved its 13th consecutive quarter of year-over-year revenue and profit growth, reporting record net revenues of $18.9 million for FQ2 2026. This 16.3% increase was primarily driven by the company’s core home care business, which grew 18.4% […]
3 Reasons Growth Investors Will Love Electromed (ELMD)
Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks Industry Outlook Highlights Intuitive Surgical, Edwards Lifesciences and Electromed
Intuitive Surgical, Edwards and Electromed tap GenAI tailwinds as AI healthcare spending surges, despite industry under performance.
3 Medical Instrument Stocks Banking on GenAI to Tackle Industry Woes
ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.